Navigation Links
Pfenex Inc. and Boehringer Ingelheim Announce Non-Exclusive Strategic Agreement for the Use of Pfenex Expression Technology™
Date:2/15/2011

SAN DIEGO and INGELHEIM, Germany, Feb. 15, 2011 /PRNewswire/ -- Pfenex Inc., an industry leader in protein expression through the Pfenex Expression Technology™ platform and Boehringer Ingelheim International GmbH, a leading pharmaceutical company and global leader in biopharmaceutical contract development and manufacture, announced today that they have entered into a strategic agreement. It provides Boehringer Ingelheim with non-exclusive access to the Pfenex Expression Technology. Under the terms of the multi-year agreement, Pfenex Inc. will engineer production strains and processes for Boehringer Ingelheim's proprietary molecules, and molecules from Boehringer Ingelheim's contract manufacturing customers. This collaboration provides Boehringer Ingelheim and their customers with access to an industry-leading expression platform to enable preclinical and clinical development to progress much more quickly and efficiently.

"We are very pleased to have established this agreement with Boehringer Ingelheim," said Dr Bertrand Liang, CEO of Pfenex Inc. "This partnership combines a cutting edge expression technology with the leading innovative pharmaceutical company and contract services provider, facilitating the speed and reliability with which important new drugs can be brought to patients."

"This collaboration extends our contract manufacturing service portfolio by an additional high expression system and is a further step in our strategy to offer customers leading technologies," stated Simon Sturge, Corporate SVP of the Biopharmaceuticals Division at Boehringer Ingelheim. "The Pfenex Expression Technology™ delivers excellent expression rates, and we are looking forward to realizing customer projects with this technology."

About Pfenex Inc.

Pfenex Inc. is a protein production company leveraging the unique and powerful Pfenex Expression Technology™ platform based on the microorganism, Pseudomonas fluorescens, for the production of research proteins, reagent proteins, biosimilars and innovator biopharmaceuticals. For more information please visit www.pfenex.com

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and more than 41,500 employees. Since it was founded in 1885, the family-owned company has been committed for 125 years to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2009, Boehringer Ingelheim posted net sales of 12.7 billion euro while spending 21% of net sales in its largest business segment Prescription Medicines on research and development.

For more information please visit www.boehringer-ingelheim.com.

Today, Boehringer Ingelheim is one of the world's leading companies for contract development and manufacture of biopharmaceuticals. All types of services from mammalian cell line or microbial strain development to final drug production can be delivered within a one-stop-shop concept. Boehringer Ingelheim delivers services for pre-clinical development up to global market supply with a strong commitment to its customers at its manufacturing facilities for mammalian cell culture and microbial fermentation. Boehringer Ingelheim has brought 18 molecules to market and has  many  years  of  experience  in  multiple  molecule  classes  such  as monoclonal antibodies, recombinant proteins, interferons, enzymes, fusion molecules and plasmid DNA. Furthermore, high-titer platform technologies for new antibody mimetic formats such as scaffold proteins and antibody fragments are available for the manufacture of customer products.

For more information contact: bio-cmo@boehringer-ingelheim.com or www.biopharma-cmo.com


'/>"/>
SOURCE Pfenex Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pfenex Grants Exclusive License to Merck & Co., Inc. for the Production of Proteins for Undisclosed Vaccine Program
2. Pfenex Inc. Awarded Contract With the United States Federal Government Potentially Totaling Up to $18.8 Million to Develop a Robust Pfenex Expression Technology Based Process for the Production of Bulk Recombinant Protective Antigen (rPA) From Anthr
3. Pfenex Inc. Establishes Reagent Protein Distribution Agreement With Cedarlane Corporation
4. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
5. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
6. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
7. Boehringer Ingelheim Unveils Diabetes Pipeline
8. Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business From Pfizer
9. Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile
10. New Boehringer Ingelheim Science Quest Mobile Laboratory Brings Hands-On Science Education to Priority Connecticut Elementary Schools
11. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2016)... 19, 2016 At the 18 th ... Amsterdam , (May 15-19), Elekta announced ... radiosurgery system available, has been used in the treatment ... tumors, vascular malformations and functional disorders. Today, ... patients every year in hundreds of leading hospitals and ...
(Date:5/19/2016)... A new report published ... Market Opportunities and Forecasts, 2014 - 2022, states ... million in 2015. The MRI-guided biopsy segment held ... to maintain this trend over the forecast period. ... , To know more about the ...
(Date:5/19/2016)... 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... the treatment of grievous blood-based disorders with significant unmet ... presented in a poster session at the European Hematology ... Copenhagen . The presentations will include additional data ... cell disease (SCD), including 90-day data from a cohort ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... 2016 , ... The old expression “a pain in the neck” takes on ... misunderstood, whiplash should be swiftly diagnosed and treated if those affected want to quickly ... Spine Center . , So named because of the whip-like, rapid back-and-forth neck ...
(Date:5/24/2016)... ... May 24, 2016 , ... After graduating from Cornell, ... the next decade in hospitals, on medication, living on Social Security disability and staying ... Illness and How I Beat It!” (published by Balboa Press), Alexander shares how he ...
(Date:5/24/2016)... ... ... Dignity Health has announced it will be opening a new freestanding emergency room ... Arizona General Hospital, which opened last year in the West Valley. , Linda ... will complement Dignity Health’s existing hospitals’ emergency departments. “We are focused on providing ...
(Date:5/24/2016)... Linda, CA (PRWEB) , ... May 24, 2016 ... ... fluorescent cell imaging; high content imaging; multiplex immunoassays are widely used for cell ... important for labs to maximize their quality and efficiency in these areas. , ...
(Date:5/23/2016)... ... May 23, 2016 , ... On Sunday, May 15, Rockynol ... 64-room assisted living center. After 18 months of construction, the new state-of-the-art structure ... building provides the latest in assisted living amenities and services, offering six different ...
Breaking Medicine News(10 mins):